Spark Neuro
SPARK Neuro is an FDA-cleared EEG-based dementia diagnostic platform serving Medicare Advantage health plans and healthcare providers. Its SPARK Scan uses proprietary machine learning and fractal signal processing to detect and differentiate dementia causes with over 90% accuracy, closing a major care gap.
- Company typePrivate
- Founded2017
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Spark Neuro does
SPARK Neuro is a New York-based neuroscience company founded in 2017 that has pivoted from its original neuromarketing focus to clinical dementia diagnosis. Its core product, SPARK Scan, is an FDA-cleared EEG-based screening tool that uses a proprietary machine-learning platform built on patent-pending Fractal Dimension Distributions (FDD) signal processing to detect and differentiate between dementia-causing diseases. The technology achieves 90%+ disease classification accuracy, 82% screening true positive rate, 96% accuracy in detecting Alzheimer's, and 80%+ accuracy in differentiating between Alzheimer's, Parkinson's, and Dementia with Lewy Bodies. SPARK Neuro has accumulated 900+ EEG datasets since 2021, secured 2 FDA clearances, and supported 5 clinical trials as of 2025.
The company sells primarily to enterprise health plans, with Medicare Advantage plans as the principal buyer. The value proposition is anchored on closing the dementia care gap—approximately 40% of cases go undiagnosed—by enabling population health screening that captures RAF adjustments and reduces downstream care costs. Secondary buyers include healthcare providers, particularly primary care physicians who handle 80% of dementia diagnoses but lack time for thorough evaluations. Named enterprise relationships include Humana, Mayo Clinic, Johns Hopkins Medicine, and the National Institute on Aging. Pricing is quote-based, recurring, and enterprise-tendered. In 2024, SPARK Neuro launched Spark Predict, a separate claims intelligence product that extends its data assets into AI-powered natural language data querying.
SPARK Neuro is a privately held, venture-backed company headquartered at 224 W 35th St, New York. It has raised approximately $35M+ in cumulative funding across multiple rounds, including a $13.5M Series A in October 2024. The leadership team combines clinical and commercial depth, including Founder & CEO Spencer Gerrol, President & COO Marinela Gombosev (scaled a neurodiagnostic device to 450 clinics), CSO Harry Leider (former Walgreens CMO), and Medical Director Richard Caselli (former Mayo Clinic Department of Neurology Chair with 300+ publications).
Spark Neuro firmographics
Firmographics- Name
- Spark Neuro
- Legal name
- SPARK Neuro
- Website
- https://sparkneuro.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SPARK Neuro is an FDA-cleared EEG-based dementia diagnostic platform serving Medicare Advantage health plans and healthcare providers. Its SPARK Scan uses proprietary machine learning and fractal signal processing to detect and differentiate dementia causes with over 90% accuracy, closing a major care gap.
- Ownership category
- akta.pro rank
Spark Neuro industry classification
Industry- Product category
- Neurological Diagnostics
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM), Dementia/Alzheimer’s Care Management & Behavioral Support (HLADALAF), Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)
Keywords
Where Spark Neuro is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Spark Neuro business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D
Revenue model
- SPARK Scan Diagnostic Services: EEG-based dementia screening services sold to health plans and healthcare providers. Revenue derived from per-test or subscription-based pricing models for population health screening programs.
- Health Plan Contracts: B2B contracts with Medicare Advantage plans and health insurers to provide dementia screening services for their member populations, addressing underdiagnosis problems and RAF adjustment opportunities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise health plan pricing (quote-based) |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
Spark Neuro product offering
Product offeringCore offering
Spark Neuro sells the SPARK Scan, an FDA-cleared EEG-based dementia screening tool that uses a proprietary machine-learning platform and patent-pending Fractal Dimension Distributions to detect and differentiate causes of dementia (Alzheimer's, Parkinson's, Dementia with Lewy Bodies). The company also offers Spark Predict, a claims intelligence platform that lets users query data using natural language. Both products are sold primarily to Medicare Advantage health plans, health insurers, and large healthcare systems for population-level dementia screening and care planning.
Product overview
SPARK Neuro offers a dementia diagnosis platform centered on the SPARK Scan, an FDA-cleared EEG-based screening tool for early dementia detection. The platform is built on a proprietary machine-learning engine that analyzes brain signals to classify and differentiate dementia causes (Alzheimer's, Parkinson's, Dementia with Lewy Bodies). Supporting offerings include Spark Predict for claims data querying and a portfolio of white papers covering the SPARK Scan methodology, health outcomes, and Medicare Advantage applications.
Differentiator
Problem solved
Functional benefit
Brands
- Spark Predict: AI-powered data intelligence platform built from the claims intelligence engine behind SPARK Neuro, allowing users to ask their data questions and get answers in seconds.
- SPARK Scan
Quantifiable outcome
- 90%+ disease classification accuracy (vs 56% for alternatives)
- +5 more outcomes
Companies that use Spark Neuro
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Spark Neuro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
Spark Neuro partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- HumanacoreHealthcare partner displayed on SPARK Neuro's homepage. Humana is a major health insurance company, suggesting a commercial relationship for dementia care gap solutions.
- Mayo CliniccoreHealthcare system partner displayed on homepage. Mayo Clinic is a premier medical institution, indicating clinical validation or collaboration in dementia diagnosis.
- Johns Hopkins MedicinecoreHealthcare system partner displayed on homepage. Johns Hopkins is a leading medical institution, suggesting clinical validation or research collaboration.
- National Institute on AgingcoreGovernment research partner displayed on homepage. NIoH is part of NIH, suggesting research collaboration and validation in dementia/brain health.
Scale indicators13 records
Recent moves6 records
Expansion highlights5 records
Spark Neuro competitors and assessment
Company assessmentDirect peers
- C2N Diagnostics: C2N Diagnostics markets PrecivityAD, a blood-based Alzheimer's diagnostic test with comparable accuracy claims and payer-facing commercialization. Both companies target early dementia detection with clinical-grade accuracy and pursue health plan and health system partnerships.
- Quanterix: Quanterix operates a high-sensitivity biomarker platform (Simoa) used for blood-based neurodegenerative disease detection and pharma research. It directly competes for the same payer and pharmaceutical customer wallet that SPARK targets, with overlapping indications in Alzheimer's and related dementias.
- Linus Health: Linus Health offers a digital cognitive assessment platform combining tablet-based tests with AI analytics for early dementia detection. Both SPARK and Linus compete for health system and payer contracts focused on closing the dementia diagnosis gap.
- Cognito Therapeutics: Cognito Therapeutics develops neurotechnology-based therapies and diagnostics for neurodegenerative disease. It overlaps with SPARK in brain-signal-based measurement of cognitive decline and shares a similar EEG/neurophysiology technology foundation.
- Altoida: Altoida uses AI-driven digital biomarkers (AR-based cognitive assessments on smartphones/tablets) for early Alzheimer's detection. Both companies pursue FDA-cleared, non-invasive, task-based alternatives to traditional cognitive screening and target similar payer and pharma customers.
- BrainCheck: BrainCheck provides a digital cognitive assessment platform used by clinicians and health systems for dementia screening. It competes in the same workflow-replacement position versus paper-based screeners that SPARK Scan targets.
- Neurotrack: Neurotrack develops digital cognitive assessment tools for early detection and monitoring of cognitive decline. Both companies target health plans, health systems, and pharmaceutical companies with non-invasive screening solutions.
Broad incumbents
- Roche (Elecsys AD diagnostics): Roche has commercialized Elecsys CSF and blood-based Alzheimer's biomarker assays with FDA breakthrough designation, and operates a global diagnostics infrastructure that dwarfs SPARK's. It represents the most significant incumbent threat in the payer-reimbursed Alzheimer's diagnostic category.
- Eli Lilly (Alzheimer's diagnostics and therapeutics): Eli Lilly is both a leader in disease-modifying Alzheimer's therapeutics (Kisunla/donanemab) and an active developer of companion diagnostics. Its scale and integrated therapeutic-diagnostic roadmap represent a long-term strategic incumbent for any early-detection company, including SPARK.
Emerging players
- Cleveland Diagnostics: Cleveland Diagnostics is developing blood-based diagnostics for prostate and other cancers and is expanding into neurodegenerative disease biomarkers. It is an emerging competitor in the same blood-based diagnostic category that could pressure EEG-based screening workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Spark Neuro social profiles
Digital presenceSpark Neuro compliance and trust
Trust signalCompliance1 record
Spark Neuro financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spark Neuro leadership team
Management profileNumber of profiles
Profiles7 records
Spark Neuro funding detail
Funding detailFunding overview
Funding rounds2 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spark Neuro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spark Neuro
What does Spark Neuro do?
Spark Neuro sells the SPARK Scan, an FDA-cleared EEG-based dementia screening tool that uses a proprietary machine-learning platform and patent-pending Fractal Dimension Distributions to detect and differentiate causes of dementia (Alzheimer's, Parkinson's, Dementia with Lewy Bodies). The company also offers Spark Predict, a claims intelligence platform that lets users query data using natural language. Both products are sold primarily to Medicare Advantage health plans, health insurers, and large healthcare systems for population-level dementia screening and care planning.
Is Spark Neuro a public or private company?
Spark Neuro is a private company. It is classified as venture growth investor backed and is currently operating.
When was Spark Neuro founded?
Spark Neuro was founded in 2017. It employs 11 to 50 people.
Where is Spark Neuro based?
Spark Neuro is headquartered in New York, United States, in the North America region.
How does Spark Neuro make money?
Two revenue lines are on record. SPARK Scan Diagnostic Services are the primary driver. The others are health Plan Contracts.
Who are Spark Neuro's main competitors?
Direct peers on record are C2N Diagnostics, Quanterix, Linus Health, Cognito Therapeutics, Altoida, BrainCheck and Neurotrack. Broad incumbents are Roche (Elecsys AD diagnostics) and Eli Lilly (Alzheimer's diagnostics and therapeutics). Cleveland Diagnostics is listed as an emerging player.
Does Spark Neuro have an API?
No public API is recorded for Spark Neuro.
What industry is Spark Neuro in?
Spark Neuro's product category is Neurological Diagnostics. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACAOAM, Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms. Its NAICS code is 5417 and its SIC code is 8731.